MBRX News and Press, Moleculin Biotech Inc. From 04/08/20

April 8, 2020 Palm Beach, FL – April 8, 2020 – The search for vaccines and treatments for the global health crises is now focusing on medicines that are presently approved for other ailments. A recent article in the LA Times discussed this issue saying that when ...

Nano cap Moleculin Biotech (NASDAQ: MBRX ) announces the results of in vitro testing in Germany showing that 2-deoxy-D-glucose (2-DG) totally stopped the replication of the SARS-CoV-2 virus. Specifically, researchers at the University of Frankfurt reported that inhibiting glycolysis (sug...

HOUSTON , April 8, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that independent research found 2-deoxy-D-glucose ("2-DG") to reduce repl...

HOUSTON , April 2, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it has completed the latest (210 mg/m 2...

NEW YORK, March 30, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced that the presentations from its inaugural conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and interactive...

NEW YORK, March 24, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its inaugural event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and...

HOUSTON, March 24, 2020 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Walter Kl...

VANCOUVER, British Columbia, March 24, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD” ) a clinical stage pharmaceutical company , announces it has entered into a development agreement (the “ Agreement...

Moleculin Biotech (NASDAQ: MBRX ) has filed a new patent application covering the use of WP1122 and its analogs as therapies to limit the ability of coronavirus and other viruses to replicate. More news on: Moleculin Biotech, Inc., Healthcare stocks news, Stocks on the move, Read mor...

HOUSTON , March 20, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that a new patent application has been...